World Health Organization, 20 Appia Avenue, Geneva, Switzerland.
Global Immunization Division, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta GA, USA.
Vaccine. 2020 May 6;38(21):3800-3807. doi: 10.1016/j.vaccine.2020.01.018. Epub 2020 Jan 23.
For lifetime protection against diphtheria and tetanus, the World Health Organization (WHO) recommends six doses of diphtheria and tetanus containing vaccines. Td (reduced diphtheria toxoid, ≥2-5 IU) vaccines are currently licensed for ages 7 years and older, but use of Td vaccine for ages 4 years and older would have advantages for immunization programs in many low- and middle-income countries. For this reason, WHO convened an expert consultation to review the currently available evidence for the use of Td vaccine from 4 to 7 years of age which concluded: (1) no relevant biological difference in immune response in the relevant age group compared with children over 7 years of age; (2) adequate seroprotection in several studies with Td vaccine in the 4-7 age group and many studies using combination vaccines; (3) durable and protective response of at least 9-11 years duration in several longitudinal and modelling studies, (4) less reactogenicity compared with use of full-dose diphtheria vaccine, potentially improving the vaccination experience; and (5) adequate control of diphtheria in several countries using Td-containing combination vaccines in 4-7 year old children. On this basis, the experts concluded that from a programmatic perspective, Td vaccine given in ages 4-7 years, as a second booster dose in a six-dose series, would provide adequate protection against diphtheria and tetanus and recommended steps to include this change in age extension listed in the package insert.
为了终生预防白喉和破伤风,世界卫生组织(WHO)建议接种六剂含白喉和破伤风类毒素的疫苗。目前,Td(降低白喉毒素,≥2-5IU)疫苗获准用于 7 岁及以上人群,但在 4 岁及以上人群中使用 Td 疫苗对许多中低收入国家的免疫规划具有优势。为此,世卫组织召集了一次专家协商会议,以审查目前可用于 4 至 7 岁儿童的 Td 疫苗使用情况,该会议得出结论:(1)在相关年龄组与 7 岁以上儿童相比,免疫反应没有明显的生物学差异;(2)在 4-7 岁年龄组使用 Td 疫苗和许多使用联合疫苗的研究中,均有足够的血清保护率;(3)在几项纵向和建模研究中,至少有 9-11 年的持久和保护反应;(4)与使用全剂量白喉疫苗相比,反应原性较低,可能改善接种体验;(5)在几个国家中,使用 Td 含联合疫苗在 4-7 岁儿童中,对白喉的控制效果良好。在此基础上,专家们得出结论,从规划角度来看,在 4-7 岁年龄组接种 Td 疫苗,作为六剂系列中的第二剂加强针,将提供对白喉和破伤风的充分保护,并建议在接种说明书中列入将这一年龄组扩大的步骤。